AsianScientist (Jul. 30, 2013) – Bristol-Myers Squibb Company and Samsung BioLogics today announced the companies have entered into a ten-year agreement under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.
Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.
“We are pleased to announce this strategic manufacturing relationship with Bristol-Myers Squibb and look forward to delivering best-in-class manufacturing services with the highest global quality standards,” said Tae-Han Kim, president and CEO of Samsung BioLogics.
The South Korean-based Samsung BioLogics is a contract process development and cGMP manufacturing for biopharmaceutical companies, with an emphasis on monoclonal & recombinant production.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.